Abstract
The European Ombudsman is an independent and impartial body that holds the EU administration to account. The Ombudsman deals with complaints lodged against the European Medicines Agency, most of which concern lack of transparency. In dealing with these complaints, the Ombudsman has underlined the importance of ensuring that European citizens trust the Agency and have confidence in the important work it carries out on their behalf.
During the course of 2012, the European Ombudsman issued a draft recommendation to the Agency in relation to the latter’s application of the EU’s Paediatric Regulation. Specifically, the case concerned the Agency’s procedures for deciding whether pharmaceutical companies should be obliged to carry out studies to investigate whether a pharmaceutical product could be used to treat children. The case is a useful illustration of the Ombudsman’s essential role in holding the European Medicines Agency to account. More generally, it helps demonstrate that the Union has inbuilt checks and balances that seek to ensure that its institutions act legally, in full respect of fundamental rights, and in accordance with principles of good administration.
The points made, and any possible errors, in this chapter are solely attributable to the author. The views expressed are not necessarily supported by the Ombudsman.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Notes
- 1.
Regulation (EC) No. 1049/2001 of the European Parliament and of the Council of 30 May 2001 regarding public access to European Parliament, Council and Commission documents, OJ 2001 L 145 p. 43.
- 2.
See Article 73 of Regulation (EC) No. 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency, OJ 2004 L 136, p. 1.
- 3.
European Medicines Agency policy on access to documents concerning medicines for human and veterinary use (ref EMA/110196/2006), adopted on 30 November 2010, effective as from 1 December 2010.
- 4.
See in particular the Ombudsman’s decisions in case 2560/2007/BEH, available at: http://www.ombudsman.europa.eu/en/cases/decision.faces/en/5459/html.bookmark and in case 2493/2008/FOR, available at: http://www.ombudsman.europa.eu/en/cases/decision.faces/en/11360/html.bookmark. This latter case is the example provided above.
- 5.
Regulation (EC) No. 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No. 726/2004, OJ 2006 L 378, p. 1.
- 6.
The draft recommendation is available at: http://www.ombudsman.europa.eu/en/cases/draftrecommendation.faces/en/11553/html.bookmark.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 American Association of Pharmaceutical Scientists
About this chapter
Cite this chapter
Agnew, R. (2014). Checks and Balances in the EU: The Role of the European Ombudsman, with a Focus on the Paediatric Regulation. In: Bar-Shalom, D., Rose, K. (eds) Pediatric Formulations. AAPS Advances in the Pharmaceutical Sciences Series, vol 11. Springer, New York, NY. https://doi.org/10.1007/978-1-4899-8011-3_29
Download citation
DOI: https://doi.org/10.1007/978-1-4899-8011-3_29
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4899-8010-6
Online ISBN: 978-1-4899-8011-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)